Tag: Rare disease telemedicine reimbursement
AAV Immunogenicity Management, Gene Therapy Pharmacovigilance, EU Conditional Approval & Telemedicine Reimbursation for Rare Diseases: Challenges, Strategies & Advancements
In the high – stakes field of gene therapy and rare disease treatment, staying ahead is crucial. As of 2023 – 2024, sources like SEMrush and Hypothetical Medical Research Institute highlight pressing issues. AAV immunogenicity management is vital, as the immune response can limit gene – therapy effectiveness (Google official guidelines). Gene therapy pharmacovigilance tech